44eb0b78-9761-4131-b831-85e765a24e6b
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 67.0499657768652
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.420
- INTERFERON_ALPHA_RESPONSE+0.400
- MYOGENESIS+0.390
- ANGIOGENESIS+0.370
- INTERFERON_GAMMA_RESPONSE+0.350
- KRAS_SIGNALING_DN+0.290
- APICAL_JUNCTION+0.270
- HEDGEHOG_SIGNALING+0.270
- ALLOGRAFT_REJECTION+0.260
- UV_RESPONSE_DN+0.260
Top 10 suppressed
- MYC_TARGETS_V2-0.680
- MYC_TARGETS_V1-0.600
- E2F_TARGETS-0.590
- G2M_CHECKPOINT-0.500
- MTORC1_SIGNALING-0.500
- OXIDATIVE_PHOSPHORYLATION-0.470
- UNFOLDED_PROTEIN_RESPONSE-0.470
- GLYCOLYSIS-0.410
- CHOLESTEROL_HOMEOSTASIS-0.400
- DNA_REPAIR-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CV-5444-01A-02R-1514-07 | — | — | 0.930 |
| 2 | TCGA-DK-AA6S-01A-21R-A39I-07 | — | — | 0.919 |
| 3 | 895018d4-b355-4339-8c60-186478ae6551 | — | — | 0.914 |
| 4 | TCGA-K4-A3WS-01A-11R-A22U-07 | — | — | 0.911 |
| 5 | 20040019.LumA | — | A | 0.910 |
| 6 | SRR975557 | — | — | 0.909 |
| 7 | GSM5359411 | — | — | 0.907 |
| 8 | 59f108c6-677f-4cf2-89fd-6bd15133dd6f | — | — | 0.905 |
| 9 | SRR15069598 | — | — | 0.905 |
| 10 | TCGA-98-A53C-01A-11R-A262-07 | — | cohortMD2 | 0.905 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.420 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.400 | Inavolisib | — uncovered |
| MYOGENESIS | 0.390 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.370 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.350 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.290 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.270 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.270 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.260 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.260 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.240 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.230 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.210 | Cobimetinib | — uncovered |
| COAGULATION | 0.180 | Binimetinib | — uncovered |
| COMPLEMENT | 0.130 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.070 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.060 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.040 | Inavolisib | — uncovered |
| APOPTOSIS | 0.020 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.020 | Idelalisib | — uncovered |